Oxygen carriers and cancer chemo- and radiotherapy sensitization: Bench to bedside and back

Cancer Treatment Reviews

Volumn 33, Issue 8, 2007, Pages 757-761

  Yu, Minghua ^a,b   Dai, Min ^a   Liu, Qian ^c   Xiu, Ruijuan ^a  

^a Chinese Academy of Medical Sciences   (China)

^b HUBEI UNIVERSITY OF MEDICINE   (China)

^c PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Cancer therapy; Drug resistance; Hypoxia; Oxygen carriers; Radiation sensitizing agents

Indexed keywords

BLEOMYCIN; BLOOD SUBSTITUTE; CARBOGEN; CARBOPLATIN; CARMUSTINE; CATALASE; CHLOROZOTOCIN; CISPLATIN; CROSS LINKED HEMOGLOBIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOSOL; FLUOSOL DA; HEMOGLOBIN; IFOSFAMIDE; LOMUSTINE; MACROGOL; MELPHALAN; MONOPHENOL MONOOXYGENASE; NITROSOUREA; OXYGEN; PERFLUORO COMPOUND; PERFLUOROOCTYL BROMIDE; PERFLUOROPENTANE; PLASMA SUBSTITUTE; POLYMERIZED HEMOGLOBIN; PORPHYRIN; SUPEROXIDE DISMUTASE; THIOTEPA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANEMIA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHEMOSENSITIZATION; CLINICAL TRIAL; EMULSION; ERYTHROCYTE; EXPERIMENTAL NEOPLASM; HUMAN; INFARCTION; NONHUMAN; OXYGEN THERAPY; RADIOSENSITIZATION; REVIEW; TISSUE OXYGENATION; UNSPECIFIED SIDE EFFECT;

ANIMALS; BLOOD SUBSTITUTES; CELL HYPOXIA; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; RADIATION-SENSITIZING AGENTS;

EID: 36148991843     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2007.08.002     Document Type: Review

References (63)

1. Melillo G. Targeting hypoxia cell signaling for cancer therapy. Cancer Metastasis Rev 26 (2007) 341-352
2. Brown J.M., and Wilson W.R. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4 (2004) 437-447
3. Overgaard J., and Horsman M.R. Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol 6 (1996) 10-21
4. Kaanders J.H., Bussink J., and van der Kogel A.J. ARCON: a novel biology-based approach in radiotherapy. Lancet Oncol 3 (2002) 728-737
5. Hoogsteen I.J., Pop L.A., Marres H.A., et al. Oxygen-modifying treatment with ARCON reduces the prognostic significance of hemoglobin in squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 64 (2006) 83-89
6. Winslow R.M. Red cell substitutes. Semin Hematol 44 (2007) 51-59
7. Riess J.G. Oxygen carriers ("blood substitutes") - raison d'etre, chemistry, and some physiology. Chem Rev 101 (2001) 2797-2920
8. Rockwell S., Irvin C.G., and Kelley M. Preclinical studies of a perfluorochemical emulsion as an adjunct to radiotherapy. Int J Radiat Oncol Biol Phys 15 (1988) 913-920
9. Moulder J.E., and Fish B.L. Intermittent use of a perfluorochemical emulsion (Fluosol-DA 20%) and carbogen breathing with fractionated irradiation. Int J Radiat Oncol Biol Phys 15 (1988) 1193-1196
10. Teicher B.A., and Rose C.M. Perfluorochemical emulsions can increase tumor radiosensitivity. Science 223 (1984) 934-936
11. Teicher B.A., and Rose C.M. Oxygen-carrying perfluorochemical emulsion as an adjuvant to radiation therapy in mice. Cancer Res 44 (1984) 4285-4288
12. Rockwell S., Mate T.P., Irvin C.G., and Nierenburg M. Reactions of tumors and normal tissues in mice to irradiation in the presence and absence of a perfluorochemical emulsion. Int J Radiat Oncol Biol Phys 12 (1986) 1315-1318
13. Rockwell S. Use of a perfluorochemical emulsion to improve oxygenation in a solid tumor. Int J Radiat Oncol Biol Phys 11 (1985) 97-103
14. Morton J.D., Porter E., Yabuki H., Nath R., and Rockwell S. Effects of a perfluorochemical emulsion on the response of BA1112 rat rhabdomyosarcomas to continuous low-dose-rate irradiation. Radiat Res 124 (1990) 178-182
15. Martin D.F., Porter E.A., Rockwell S., and Fischer J.J. Enhancement of tumor radiation response by the combination of a perfluorochemical emulsion and hyperbaric oxygen. Int J Radiat Oncol Biol Phys 13 (1987) 747-751
16. Martin D.F., Porter E.A., Fischer J.J., and Rockwell S. Effect of a perfluorochemical emulsion on the radiation response of BA1112 rhabdomyosarcomas. Radiat Res 112 (1987) 45-53
17. Teicher B.A., Holden S.A., Northey D., Dewhirst M.W., and Herman T.S. Therapeutic effect of infused Fluosol-DA/carbogen with ephedrine, flunarizine, or nitroprusside. Int J Radiat Oncol Biol Phys 26 (1993) 103-109
18. Waldow S.M., Lustig R.A., Brass-Marlow E.L., Nunno M.P., Holst R.J., and Wallner P.E. Effect of Fluosol-DA 20% and oxygen on response of C57BL/6 mice to whole-body irradiation. Int J Radiat Oncol Biol Phys 19 (1990) 665-668
19. Evans R.G., Kimler B.F., Morantz R.A., and Batnitzky S. Lack of complications in long-term survivors after treatment with Fluosol and oxygen as an adjuvant to radiation therapy for high-grade brain tumors. Int J Radiat Oncol Biol Phys 26 (1993) 649-652
20. Lustig R., McIntosh-Lowe N., Rose C., et al. Phase I/II study of Fluosol-DA and 100% oxygen as an adjuvant to radiation in the treatment of advanced squamous cell tumors of the head and neck. Int J Radiat Oncol Biol Phys 16 (1989) 1587-1593
21. Lustig R., Lowe N., Prosnitz L., et al. Fluosol and oxygen breathing as an adjuvant to radiation therapy in the treatment of locally advanced non-small cell carcinoma of the lung: results of a phase I/II study. Int J Radiat Oncol Biol Phys 19 (1990) 97-102
22. Evans R.G., Kimler B.F., Morantz R.A., et al. A phase I/II study of the use of Fluosol as an adjuvant to radiation therapy in the treatment of primary high-grade brain tumors. Int J Radiat Oncol Biol Phys 19 (1990) 415-420
23. Dowling S., Fischer J.J., and Rockwell S. Fluosol and hyperbaric oxygen as an adjunct to radiation therapy in the treatment of malignant gliomas: a pilot study. Biomater Artif Cells Immobil Biotechnol 20 (1992) 903-905
24. Teicher B.A., Herman T.S., and Jones S.M. Optimization of perfluorochemical levels with radiation therapy in mice. Cancer Res 49 (1989) 2693-2697
25. Teicher B.A., Herman T.S., and Jones S.M. Influence of scheduling, dose, and volume of administration of a perfluorochemical emulsion on tumor response to radiation therapy. Int J Radiat Oncol Biol Phys 19 (1990) 945-951
26. Teicher B.A., Herman T.S., Hopkins R.E., and Menon K. Effect of oxygen level on the enhancement of tumor response to radiation by perfluorochemical emulsions or a bovine hemoglobin preparation. Int J Radiat Oncol Biol Phys 21 (1991) 969-974
27. Tanaka J., Holden S.A., Herman T.S., and Teicher B.A. Response of subpopulations of the FSall C fibrosarcoma to low dose X-rays and various potential enhancing agents. Anticancer Res 12 (1992) 1029-1033
28. Thomas C., Lartigau E., Malaise E.P., and Guichard M. New high O2 carrying perfluorochemical emulsions and/or carbogen: reactions of a human tumor xenograft to irradiation. Int J Radiat Oncol Biol Phys 16 (1989) 1157-1160
29. Rockwell S., Kelley M., Irvin C.G., et al. Preclinical evaluation of Oxygent as an adjunct to radiotherapy. Biomater Artif Cells Immobil Biotechnol 20 (1992) 883-893
30. Teicher B.A., Herman T.S., and Menon K. Enhancement of fractionated radiation therapy by an experimental concentrated perflubron emulsion (Oxygent) in the Lewis lung carcinoma. Biomater Artif Cells Immobil Biotechnol 20 (1992) 899-902
31. Guichard M., Lartigau E., Martin L., et al. Tumor oxygenation after (1) carbogen and/or perflubron emulsion administration in tumor xenografts (2) carbogen administration in patients. Artif Cells Blood Substit Immobil Biotechnol 22 (1994) 1355-1360
32. Teicher B.A. Combination of perfluorochemical emulsions and carbogen breathing with cancer chemotherapy. Artif Cells Blood Substit Immobil Biotechnol 22 (1994) 1109-1120
33. Stern S., and Guichard M. Efficacy of agents counteracting hypoxia in fractionated radiation regimes. Radiother Oncol 41 (1996) 143-149
34. Koch C.J., Oprysko P.R., Shuman A.L., Jenkins W.T., Brandt G., and Evans S.M. Radiosensitization of hypoxic tumor cells by dodecafluoropentane: a gas-phase perfluorochemical emulsion. Cancer Res 62 (2002) 3626-3629
35. Fingar V.H., Mang T.S., and Henderson B.W. Modification of photodynamic therapy-induced hypoxia by FLuosol-DA (20%) and carbogen breathing in mice. Cancer Res 48 (1988) 3350-3354
36. Chowdhary R.K., Cundall R.B., and Morgan C.G. Influence of fluorocarbon emulsions on porphyrin-sensitised oxidation of histidine. Photochem Photobiol 51 (1990) 395-399
37. Kamuhabwa A.R., Huygens A., Roskams T., and De Witte P.A. Enhancing the photodynamic effect of hypericin in human bladder transitional cell carcinoma spheroids by the use of the oxygen carrier, perfluorodecalin. Int J Oncol 28 (2006) 775-780
38. Lowe K.C., Akande S.L., Bonnett R., White R.D., and Berenbaum M.C. Protective effects of a novel perfluorochemical emulsion in photodynamic therapy. Biomater Artif Cells Immobil Biotechnol 20 (1992) 925-927
39. Teicher B.A., Lazo J.S., Merrill W.W., Filderman A.E., and Rose C.M. Effect of Fluosol-DA/O2 on the antitumor activity and pulmonary toxicity of bleomycin. Cancer Chemother Pharmacol 18 (1986) 213-218
40. Martin D.F., Kimler B.F., Evans R.G., Morantz R.A., and Vats T.S. Potentiation of rat brain tumor therapy by fluosol and carbogen. NCI Monogr (1988) 119-122
41. Teicher B.A., Herman T.S., and Rose C.M. Effect of Fluosol-DA on the response of intracranial 9L tumors to X rays and BCNU. Int J Radiat Oncol Biol Phys 15 (1988) 1187-1192
42. 2 on tumor-cell and bone-marrow cytotoxicity of nitrosoureas in mice bearing FSA-II fibrosarcoma. Int J Cancer 38 (1986) 285-288
43. Teicher B.A., McIntosh-Lowe N.L., and Rose C.M. Effect of various oxygenation conditions and fluosol-DA on cancer chemotherapeutic agents. Biomater Artif Cells Artif Organs 16 (1988) 533-546
44. Kim G.E., and Song C.W. The influence of Fluosol-DA and carbogen breathing on the antitumor effects of cyclophosphamide in vivo. Cancer Chemother Pharmacol 25 (1989) 99-102
45. Teicher B.A., Holden S.A., and Jacobs J.L. Approaches to defining the mechanism of enhancement by Fluosol-DA 20% with carbogen of melphalan antitumor activity. Cancer Res 47 (1987) 513-518
46. Teicher B.A., Waxman D.J., Holden S.A., et al. Evidence for enzymatic activation and oxygen involvement in cytotoxicity and antitumor activity of N,N′,N″- triethylenethiophosphoramide. Cancer Res 49 (1989) 4996-5001
47. Holden S.A., Teicher B.A., Ha C., Ara G., and Herman T.S. Enhancement by perflusion emulsion (Oxygent) and carbogen breathing of the tumor growth delay of the FSaIIC fibrosarcoma after treatment with antitumor alkylating agents. Biomater Artif Cells Immobil Biotechnol 20 (1992) 895-898
48. Teicher B.A., Holden S.A., Ara G., Ha C.S., Herman T.S., and Northey D. A new concentrated perfluorochemical emulsion and carbogen breathing as an adjuvant to treatment with antitumor alkylating agents. J Cancer Res Clin Oncol 118 (1992) 509-514
49. Teicher B.A., Holden S.A., Dupuis N.P., et al. Oxygenation of the rat 9L gliosarcoma and the rat 13672 mammary carcinoma with various doses of a hemoglobin solution. Artif Cells Blood Substit Immobil Biotechnol 22 (1994) 827-833
50. Robinson M.F., Dupuis N.P., Kusumoto T., Liu F., Menon K., and Teicher B.A. Increased tumor oxygenation and radiation sensitivity in two rat tumors by a hemoglobin-based, oxygen-carrying preparation. Artif Cells Blood Substit Immobil Biotechnol 23 (1995) 431-438
51. Teicher B.A., Schwartz G.N., Alvarez Sotomayor E., Robinson M.F., Dupuis N.P., and Menon K. Oxygenation of tumors by a hemoglobin solution. J Cancer Res Clin Oncol 120 (1993) 85-90
52. Teicher B.A., Holden S.A., Ara G., Herman T.S., Hopkins R.E., and Menon K. Effect of a bovine hemoglobin preparation (SBHS) on the response of two murine solid tumors to radiation therapy or chemotherapeutic alkylating agents. Biomater Artif Cells Immobil Biotechnol 20 (1992) 657-660
53. Teicher B.A., Dupuis N.P., Emi Y., Ikebe M., Kakeji Y., and Menon K. Increased efficacy of chemo- and radio-therapy by a hemoglobin solution in the 9L gliosarcoma. In Vivo 9 (1995) 11-18
54. Teicher B.A., Holden S.A., Menon K., Hopkins R.E., and Gawryl M.S. Effect of hemoglobin solution on the response of intracranial and subcutaneous 9L tumors to antitumor alkylating agents. Cancer Chemother Pharmacol 33 (1993) 57-62
55. Linberg R., Conover C.D., Shum K.L., and Shorr R.G. Increased tissue oxygenation and enhanced radiation sensitivity of solid tumors in rodents following polyethylene glycol conjugated bovine hemoglobin administration. In Vivo 12 (1998) 167-173
56. Nozue M., Lee I., Manning J.M., Manning L.R., and Jain R.K. Oxygenation in tumors by modified hemoglobins. J Surg Oncol 62 (1996) 109-114
57. Shorr R.G., Kwong S., Gilbert C., and Benesch R.E. Changes in the functional properties of bovine hemoglobin induced by covalent modification with polyethylene glycol. Artif Cells Blood Substit Immobil Biotechnol 27 (1999) 185-202
58. Raabe A., Gottschalk A., Hommel M., Dubben H.H., and Strandl T. No effect of the hemoglobin solution HBOC-201 on the response of the rat R1H tumor to fractionated irradiation. Strahlenther Onkol 181 (2005) 730-737
59. Gottschalk A., Raabe A., Hommel M., Rempf C., Freitag M., and Standl T. Influence of the hemoglobin solution HBOC-201 on tissue oxygenation in the rat R1H-tumor. Artif Cells Blood Substit Immobil Biotechnol 33 (2005) 379-389
60. Standl T., Horn P., Wilhelm S., et al. Bovine haemoglobin is more potent than autologous red blood cells in restoring muscular tissue oxygenation after profound isovolaemic haemodilution in dogs. Can J Anaesth 43 (1996) 714-723
61. Chang T.M. Blood substitutes based on nanobiotechnology. Trends Biotechnol 24 (2006) 372-377
62. Caswell J.E., Strange M.B., Rimmer III D.M., Gibson M.F., Cole P., et al. A novel hemoglobin-based blood substitute protects against myocardial reperfusion injury. Am J Physiol Heart Circ Physiol 288 (2005) H1796-H1801
63. George I., Yi G.H., Schulman A.R., et al. A polymerized bovine hemoglobin oxygen carrier preserves regional myocardial function and reduces infarct size after acute myocardial ischemia. Am J Physiol Heart Circ Physiol 291 (2006) H1126-H1137